Literature DB >> 28700544

Payer coverage policies for multigene tests.

Kathryn A Phillips1,2,3, Patricia A Deverka4,5, Julia R Trosman1,6,7, Michael P Douglas1, James D Chambers8,9, Christine B Weldon6,7, Andrew P Dervan10.   

Abstract

Entities:  

Year:  2017        PMID： 28700544      PMCID： PMC5553867          DOI： 10.1038/nbt.3912

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

1.  Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

2.  Closing the evidence gap in the use of emerging testing technologies in clinical practice.

Authors:  Kathryn A Phillips
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

3.  Health technology assessment and private payers' coverage of personalized medicine.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

4.  Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers.

Authors:  Michael D Graf; Denise F Needham; Nicole Teed; Trisha Brown
Journal:  Per Med       Date:  2013-05       Impact factor: 2.512

5.  Developing context-specific next-generation sequencing policy.

Authors:  Margaret Ann Curnutte; Karen L Frumovitz; Juli M Bollinger; Robert M Cook-Deegan; Amy L McGuire; Mary A Majumder
Journal:  Nat Biotechnol       Date:  2016-05-06       Impact factor: 54.908

6.  Overcoming the reimbursement barriers for clinical sequencing.

Authors:  Patricia A Deverka; David Kaufman; Amy L McGuire
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

7.  Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.

Authors:  Julia R Trosman; Christine B Weldon; R Kate Kelley; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

8.  Availability and payer coverage of BRCA1/2 tests and gene panels.

Authors:  Elizabeth Clain; Julia R Trosman; Michael P Douglas; Christine B Weldon; Kathryn A Phillips
Journal:  Nat Biotechnol       Date:  2015-09       Impact factor: 54.908

9.  Insurance coverage policies for personalized medicine.

Authors:  Andrew Hresko; Susanne B Haga
Journal:  J Pers Med       Date:  2012-10-30

10.  Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.

Authors:  Andrew P Dervan; Patricia A Deverka; Julia R Trosman; Christine B Weldon; Michael P Douglas; Kathryn A Phillips
Journal:  Genet Med       Date:  2016-09-22       Impact factor: 8.822
  10 in total
  16 in total

Review 1.  Precision Medicine: From Science To Value.

Authors:  Geoffrey S Ginsburg; Kathryn A Phillips
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

2.  Genetic Test Availability And Spending: Where Are We Now? Where Are We Going?

Authors:  Kathryn A Phillips; Patricia A Deverka; Gillian W Hooker; Michael P Douglas
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

3.  Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.

Authors:  Michael P Douglas; Stacy W Gray; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2020-07       Impact factor: 11.908

4.  Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing.

Authors:  Chloe M Reuter; Jennefer N Kohler; Devon Bonner; Diane Zastrow; Liliana Fernandez; Annika Dries; Shruti Marwaha; Jean Davidson; Elly Brokamp; Matthew Herzog; Joyce Hong; Ellen Macnamara; Jill A Rosenfeld; Kelly Schoch; Rebecca Spillmann; Joseph Loscalzo; Joel Krier; Joan Stoler; David Sweetser; Christina G S Palmer; John A Phillips; Vandana Shashi; David A Adams; Yaping Yang; Euan A Ashley; Paul G Fisher; John J Mulvihill; Jonathan A Bernstein; Matthew T Wheeler
Journal:  J Genet Couns       Date:  2019-09-03       Impact factor: 2.537

5.  Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.

Authors:  Julia R Trosman; Michael P Douglas; Su-Ying Liang; Christine B Weldon; Allison W Kurian; Robin K Kelley; Kathryn A Phillips
Journal:  Value Health       Date:  2020-03-19       Impact factor: 5.725

6.  New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare.

Authors:  K A Phillips; J R Trosman; C B Weldon; M P Douglas
Journal:  JCO Precis Oncol       Date:  2018-11-08

7.  Insurance coverage for genomic tests.

Authors:  Kathryn A Phillips; Julia R Trosman; Patricia A Deverka; Bruce Quinn; Sean Tunis; Peter J Neumann; James D Chambers; Louis P Garrison; Michael P Douglas; Christine B Weldon
Journal:  Science       Date:  2018-04-19       Impact factor: 47.728

8.  EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.

Authors:  James D Chambers; Cayla J Saret; Jordan E Anderson; Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Int J Technol Assess Health Care       Date:  2017-10-25       Impact factor: 2.188

9.  Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.

Authors:  Laura M Amendola; M Ragan Hart; Robin L Bennett; Martha Horike-Pyne; Michael Dorschner; Brian Shirts; Gail P Jarvik
Journal:  J Genet Couns       Date:  2019-07-17       Impact factor: 2.537

10.  The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.

Authors:  Kathryn A Phillips; Michael P Douglas
Journal:  J Precis Med       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.